A molecular jewel for hemophilia A treatment

Research output: Contribution to journalReview articlepeer-review


Colleges, School and Institutes

External organisations



In this issue of Blood, Seth Chhabra et al describe the engineering of a new therapeutic chimera composed of B domain-deleted (BDD) factor VIII (FVIII), FVIII-binding domain of von Willebrand factor (VWF), Fcg1 fragment, and XTEN polypeptides.1 The molecule, referred to as rFVIIIFc-VWF-XTEN or BIVV001, has a prolonged half-life that is independent from endogenous VWF and is hemostatically competent.

Bibliographic note

Funding Information: Conflict-of-interest disclosure: J.R. declares no competing financial interests. S.L.-D. is the recipient of a research grant from Sanofi Genzyme and Sobi. n Publisher Copyright: © 2020 by The American Society of Hematology. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.


Original languageEnglish
Pages (from-to)1417-1419
Number of pages3
Issue number17
Publication statusPublished - 23 Apr 2020